logo
A case of children with high lead levels in China is spotlights a public trust gap

A case of children with high lead levels in China is spotlights a public trust gap

CNN6 days ago
A case in which more than 200 kindergarten students in northwestern China were found to have abnormal blood lead levels is revealing a deep distrust in local government, as members of the public question the findings of an official investigation.
Authorities in the city of Tianshui in China's Gansu province earlier this week said eight people, including the principal of the Heshi Peixin Kindergarten, had been detained after an investigation found 233 students had been exposed to lead after school kitchen staff used inedible paint containing the toxic substance as food coloring.
The case initially generated new outrage in a country long plagued by food and environmental safety scandals.
But in the days since it has also become a lightning rod for public mistrust of official handling of such cases, in a system where there are few independent checks and officials are under pressure to resolve issues quickly.
Among the most glaring examples is the start of the Covid-19 pandemic in central China's Wuhan, when local authorities detained supposed 'rumormongers' who had tried to warn of the spread of a virus in the city as officials downplayed the outbreak.
On social media, many are questioning the credibility of the government report and aspects of the state media coverage. Some discussion appears to have been censored online in China's tightly controlled media environment, though other articles exploring the situation remain active.
One mother in the city, whose child does not attend the school that's been at the center of the official investigation, described to CNN mistrust among local families about the government's findings.
'All the parents think (food is not the actual source of the lead poisoning). But we don't know the exact reasons … how are we supposed to know anything?' the mother, who declined to be identified due to concerns about local government retaliation, told CNN in a phone interview.
'Ordinary folks like us probably have no clue – only the government knows what's really going on,' she said.
CNN has repeatedly tried to contact the Tianshui government for comment and has also reached out to China's State Council Information Office by fax. The government in its Tuesday report said the investigation was on-going and that officials from the National Health Commission and other central government departments had helped with the probe.
Among key concerns raised in online discussion are what reports suggest are serious discrepancies between the results of blood tests conducted in Tianshui and those that came back from hospitals in Xi'an, a city in a neighboring province, where some parents took their children to be tested. The Tianshui test results were never publicly disclosed.
One mother of a student at the kindergarten said a local department in Tianshui told her the blood levels of her child were normal, but a hospital in Xi'an later found her child's blood lead levels were 528 micrograms per liter, according to a report published by China National Radio (CNR). China's official guidelines classify this as 'severe lead poisoning.'
Reports from state-affiliated media found that 70 children who were tested in Xi'an had blood lead levels surpassing the threshold of lead poisoning, with six of those cases exceeding 450 micrograms per liter. A full picture of the results from all the students with abnormal levels was not publicly available.
In the investigation report, local authorities said they had conducted sampling investigations at the kindergarten and three affiliated schools and tested food samples, water, outdoor soil and other supplies and equipment. Two food samples – of cake and a corn roll – at the kindergarten, were found to have lead levels more than 2,000 times the national food safety standard for contamination.
But that didn't quell questions. 'The children only eat three-color jujube steamed cake and corn sausage rolls once or twice a week, how could they be poisoned so seriously?' one mother, who gave her surname Wu, told CNR.
Independent blogs online looking into the case have garnered tens of thousands of views. Some discussion appears to have been censored online in China's tightly controlled media environment, though other articles exploring the situation remain active.
Some of these accounts raised questions including about why the school, which authorities said used the paint to 'attract more enrollment and increase revenue,' wouldn't have just used simple food coloring, which ecommerce sites show is generally cheaper than industrial pigment.
Others raised questions about the credibility of an edited closed-circuit video released by state media alleging to show use of the coloring in the kindergarten's kitchen.
Local concerns were also fueled by memory of a 2006 lead poisoning scandal in the same district of Tianshui. Then, over 200 villagers were found to have high levels of lead in their blood during tests conducted outside Tianshui city, according to a state media commentary on the incident published at the time. The source of that lead poisoning case was never officially disclosed.
The current case has caught the attention of prominent figures in China's online ecosystem, including Hu Xijin, former editor-in-chief of state-affiliated media outlet Global Times.
'Questions about environmental pollution are valid, but those raising such concerns need to maintain objectivity in their analysis and should not treat these associative doubts as urgent alarms to spread in society,' Hu wrote on China's X-like social media platform Weibo on Wednesday.
But, he also added it was 'key for authorities providing ample information to strengthen public trust.'
Professor Stuart Khan, head of the University of Sydney's School of Civil Engineering, told CNN that blood lead level concentrations as high as those cited by state media reports about this case would 'typically require regular exposure for several weeks to months, unless there is a very acute poisoning episode' and that levels can rise progressively with 'continuous environmental exposure.'
Potential sources of contamination, such as food, soil or water, could be ruled out by conducting assessments in the broader community and family members of the children to identify who is predominately affected, said Khan, who is not involved in this case.
Lead poisoning used to be a more widespread issue in China. In 2010, the central government for the first time allocated special funds for heavy metal pollution prevention in response to at least 12 high-profile cases the previous year that left more than 4,000 people with elevated blood lead levels, according to state media.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Yahoo

time3 hours ago

  • Yahoo

Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma[Link]. Publication in this leading international academic journal indicates the strong recognition of the therapy's clinical potential and marks another significant milestone in China's progress in developing novel anti-tumor medications. Based on the study findings, a multi-regional Phase 3 clinical trial (G-HOPE-001, NCT06238843) was launched in 2024 to further evaluate IBI343 as a safe and effective treatment option for patients with advanced G/GEJ AC. Gastric cancer remains one of the most common malignant tumors in the world. According to the GLOBOCAN 2022 statistics, it ranks as the fifth most common malignant tumor and the fifth leading cause of cancer-related death globally, with an estimated 970,000 new cases and 660,000 deaths annually. Each year, China reports 359,000 new cases and 260,000 deaths from gastric cancer, representing 37.0% and 39.4% of global totals, respectively, highlighting a significant unmet medical need. CLDN 18.2 is a tight junction protein expressed in differentiated epithelial cells on the gastric mucosa under normal physiological conditions. Previous studies have revealed that Claudin18.2 is highly expressed in multiple types of cancer, including gastric cancer (60-80%), pancreatic cancer (50%), esophageal carcinoma (30-50%), and lung cancer (40-60%). Targeting CLDN18.2 with monoclonal antibodies (mAbs) and ADCs represents a promising new approach for treating gastric cancer. This published study is a global, multicenter Phase 1 clinical trial ( identifier: NCT05458219) designed to evaluate the safety, tolerability and preliminary efficacy of IBI343 in patients with advanced solid tumors. Between October 26, 2022, and June 30, 2024, a total of 116 subjects with advanced G/GEJ adenocarcinoma were enrolled to receive IBI343 monotherapy (8 in escalation and 108 in expansion). IBI343 has demonstrated encouraging tumor response and survival benefit The study analyzed the efficacy data of evaluable subjects with high expression of CLDN18.2 (≥75% tumor cells with membranous staining intensity ≥2+ by IHC), in the two dose groups of 6 mg/kg and 8 mg/kg. At 6 mg/kg (N=31), 15 patients had partial responses (PR) including 9 patients with confirmed PRs and 1 patient awaiting confirmation. The confirmed ORR was 29.0% (95% CI: 14.2-48.0) and the disease control rate (DCR) was 90.3% (95% CI: 74.2-98.0). In 9 patients with confirmed response, the median duration of response (DoR) was 5.6 months (95% CI: 2.8-7.0). The median follow-up was 10.6 months (95% CI: 9.7-11.5) for PFS and OS. The median PFS was 5.5 months (95% CI: 4.1-7.0). OS data was not mature with the current median OS of 10.8 months (95% CI: 6.8-NC). After data cutoff, response of the remaining 1 patient was confirmed on July 26, 2024 and the confirmed ORR was updated to 32.3% (95% CI: 16.7-51.4). At 8 mg/kg (N=17), 17 patients with high expression of CLDN 18.2 were evaluable. Among them, 9 patients had PRs including 8 patients had confirmed PR. The confirmed ORR 47.1% (95% CI: 23.0-72.2), and the DCR was 88.2% (95% CI: 63.6-98.5). In eight patients with confirmed response, the median DoR was 5.7 months (95% CI: 2.7-NC). Of all G/GEJ adenocarcinoma patients with high CLDN18.2 expression treated at 8 mg/kg (N=19, including 1 patient from dose escalation and 18 patients from dose expansion), the median follow-up was 8.1 months (95% CI: 7.6-8.5) for PFS and OS. The median PFS was 6.8 months (95% CI: 2.8-7.5), and the median OS was not reached with events occurred in 36.8% patients. IBI343 also demonstrated superior safety Among all patients with G/GEJ adenocarcinoma (n=116, including 8 patients with gastric cancer from the dose escalation phase), 66.4% patients (77/116) had ≥3 grade TEAEs. The most common ≥3 grade TEAEs (≥35%) were neutrophil count decreased (28.4%), white blood cell count decreased (25.9%), and anemia (16.4%). There were very few grade ≥3 gastrointestinal adverse events, including only 1.7% of grade ≥3 nausea. No interstitial lung disease of any grade was reported. Treatment-related toxicity was alleviated with adequate supportive treatment, and the overall safety was tolerable. Integrated pharmacokinetics (PK), exposure-response, safety, and efficacy data supported 6 mg/kg Q3W as the recommended Phase 2 dose (RP2D) of IBI343. This provides support for the conduct of subsequent Phase 3 trial, suggesting that IBI343 may become a new treatment option for patients with gastric cancer in the future. Professor Lin Shen, Corresponding Author, Leading Principal Investigator, from Beijing Cancer Hospital, said, "Following the eras of chemotherapy, targeted therapy and immunotherapy, ADCs have opened a new frontier in the treatment of gastrointestinal tumors. IBI343 is a new generation of Fc-silent anti-CLDN18.2 ADC that has shown encouraging clinical benefits and low gastrointestinal toxicity in Phase 1 studies. We look forward to the results of the Phase 3 study comparing IBI343 with standard treatment, aiming to ultimately reshape clinical practice, transform treatment paradigms, and usher in a new chapter in precision medicine." Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent Biologics, said, "There is a huge unmet clinical need for the treatment of advanced gastric cancer. The Phase 1 study results of IBI343 in advanced gastric and gastroesophageal junction adenocarcinoma, now published in the top international journal, Nature Medicine, further verify the clinical value of IBI343 in this population. We will work with researchers worldwide to advance the multi-regional Phase 3 clinical trial (G-HOPE-001), with the goal of establishing a new paradigm in clinical diagnosis and treatment and ultimately benefiting gastric cancer patients around the world. We are also exploring the therapeutic potential of IBI343 in pancreatic cancer and other indications." About Gastric/ Gastroesophageal Junction Adenocarcinoma Gastric cancer is one of the most prevalent malignant tumors worldwide and a leading cause of cancer-related deaths globally. The 5-year survival rate of patients with metastatic gastric cancer is less than 5%[i]. China and Japan have the highest incidence rates of gastric cancer[ii]. Currently, the standard-of-care treatments for patients with advanced metastatic gastric cancer include a chemotherapy combination of fluoropyrimidine and platinum, as well as immune checkpoint inhibitor therapy. However, systemic therapy has limited efficacy in advanced gastric cancer. In particular, the prognosis for patients with third-line or higher gastric cancer is usually poor, with fewer treatment options and shorter survival expectations. The median survival time for these patients is only about 0.5 year[iii]. Claudin, a member of the tight junction molecule family, is a key structural and functional component of epithelial tight junctions. Among them, CLDN18.2 is normally buried in gastric mucosa, but the development of malignancy leads to disruption of tight junctions and exposure of CLDN18.2 epitopes on the membrane of tumor cells[iv]. CLDN18.2 is expressed in up to 80% of patients with gastric cancer. About IBI343(Anti CLDN18.2 ADC) IBI343 is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) developed by Innovent Biologics. It specifically binds to the tumor cells expressing CLDN18.2, triggering CLDN18.2-dependent internalization of the ADC. Once inside the cell, the cytotoxic payload is released, resulting in DNA damage and ultimately apoptosis of the tumor cells. The released drug can also diffuse across the plasma membrane to reach and kill neighboring cells, resulting in a "bystander killing effect". As an innovative TOPO1i ADC, IBI343 has demonstrated tolerable safety and encouraging efficacy signals in this Phase 1 clinical studies. The therapeutic potential of IBI343 is currently being explored in tumor types such as gastric cancer and pancreatic cancer. The multi-regional Phase 3 clinical trial of IBI343 for advanced gastric / gastroesophageal junction adenocarcinoma is now recruiting patients (G-HOPE-001, NCT06238843). The relevant indication has been granted Breakthrough Therapy Designation (BTD) by China's NMPA . The multi-regional Phase 1 clinical trial of IBI343 for advanced pancreatic ductal adenocarcinoma is also enrolling patients (NCT05458219). This indication has received Fast Track Designation (FTD) from the U.S. FDA and been granted BTD by China's NMPA. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: Biologics does not recommend the use of unapproved drugs/indications. injection (Cyramza®), selpercatinib capsules (Retsevmo®) and pirtobrutinib tablets (Jayprica®) were developed by Eli Lilly and Company Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics, Inc. ("Innovent" or "Company"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. References [i] Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res. May 2014;34(5):2079-85 [ii] Xu B, Wang JM. Epidemiological study of gastric cancer[J]. Chin J Cancer Prev Treat, 2006,13(1): 81-87. [iii] Chan WL, Lam KO, So TH, et al. Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review. Ther Adv Med Oncol. 2019;11:1758835919859990. [iv] Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624-7634. View original content: SOURCE Innovent Biologics

No Kid Hungry, New York City Public Schools distributing free summer meals across 5 boroughs
No Kid Hungry, New York City Public Schools distributing free summer meals across 5 boroughs

CBS News

time3 hours ago

  • CBS News

No Kid Hungry, New York City Public Schools distributing free summer meals across 5 boroughs

New York City Public Schools has teamed up with No Kid Hungry New York to provide free meals across the five boroughs throughout the summer. Rachel Sabella, the director of No Kid Hungry New York, said the food will be distributed at a variety of places, including parks, schools, pools, libraries and food trucks. She also shared the food will not only be nutritious but tasty, serving a variety of meals from cheese sandwiches to chicken pasta. "One of the things the New York City public school does is they taste test items. So if kids don't like it, it doesn't go on the menu," Sabella said. The food truck at Haffen Park in the Baychester section of the Bronx will be serving free breakfast and lunch to kids seven days a week. Sabella stated roughly 1,000 locations throughout the city will also be serving free breakfast and lunch. "When kids have access to nutritious meals, they grow up stronger. They have higher attendance rates. They do better in school. So No Kid Hungry is really thrilled to partner with the New York City Schools and to make this program available in every community," Sabella said. To find out more information about the summer meals and locations, click here. You can also find more information by calling 311. You can email Erica with Bronx story ideas by CLICKING HERE.

Trump officials halt ‘dangerous' research, overriding NIH career scientists
Trump officials halt ‘dangerous' research, overriding NIH career scientists

Washington Post

time4 hours ago

  • Washington Post

Trump officials halt ‘dangerous' research, overriding NIH career scientists

In May, President Donald Trump signed an executive order in the Oval Office surrounded by his top health officials, vowing a crackdown on 'dangerous gain-of-function research' on viruses and pathogens that he alleged was occurring in the United States with inadequate oversight. 'It's a big deal,' Trump had said, alluding to the highly contested theory that the covid pandemic was caused by a lab leak related to such research in China.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store